WILEX announces financial figures for the 2016 fiscal year and reports on course of business
(WorldNews Germany)

Financials in line with planning -compliant manufacturing process underway for the agent Amanitin and important technology partnerships agreed for Targeted Amanitin Conjugates (ATACs) Start of preclinical development of the first ATAC candidate for the multiple myeloma indication Outlook on 2017: investments in proprietary ATAC pipeline and increase in sales revenue forecast Public conference call to be held on 30 March 2017 at 3:00 p.m. CEST Munich, 30 March 2017 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today published its financial results and annual report for the 2016 financial year (1 December 2015 - 30 November 2016) and its outlook on 2017. `We achieved several important milestones...